IDO-derived peptide vaccine/PD-L1-derived peptide vaccine (IO Biotech)
- Generic Name
- IDO-derived peptide vaccine/PD-L1-derived peptide vaccine (IO Biotech)
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Phase 2
Recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2025-02-19
- Target Recruit Count
- 15
- Registration Number
- NCT05977907
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Providence Cancer Institute, Portland, Oregon, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Phase 2
Recruiting
- Conditions
- MelanomaSquamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- IO Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT05280314
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇺🇸Massey Cancer Center, Richmond, Virginia, United States
🇩🇰Aarhus University Hospital, Aarhus, Denmark
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Phase 3
Active, not recruiting
- Conditions
- Metastatic MelanomaUnresectable Melanoma
- Interventions
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- IO Biotech
- Target Recruit Count
- 407
- Registration Number
- NCT05155254
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇦🇺Flinders Medical Centre, Bedford Park, South Australia, Australia
🇩🇰Herlev og Gentofte Hospital, Herlev, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath